Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn’s disease, asthma/COPD and acute lung injury.

As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company’s formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company’s infrastructure and core competencies

Mission Statement
Alba excels in discovering, developing and delivering superior immuno-inflammatory therapeutics, generating value for our patients, employees and shareholders.

Company Values
Our culture is based on integrity, excellence and respect for people. We continue to excel by building an organization of the most talented people, in which the individuals and the work processes are aligned to achieve the Company’s business objectives.

Vision
We create value by modifying the course of disease and facilitating innovative therapies. The core of our innovative solutions rests upon our people, our science and our molecules. Our products will address unmet clinical needs and significantly improve upon existing treatments.